title: Effect of cilostazol, a phosphodiesterase inhibitor, on carotid IMT in Japanese type 2 diabetic patients.
abstract: The aim of this study was to investigate the effect of cilostazol, a cAMP phosphodiesterase inhibitor, on carotid artery intima-media thickness (IMT) and on the incidence of cardiovascular events in Japanese subjects with type 2 diabetes. A total of 62 type 2 diabetic subjects were allocated equally to the cilostazol treatment group (n = 31) and the control group (n = 31). Carotid IMT was evaluated before and after treatment using B-mode ultrasonography. After the study period (mean +/- SD: 2.6 +/- 0.17 years), carotid IMT showed a significantly greater increase in the control group than in the cilostazol group (0.12 +/- 0.14 mm vs. 0.04 +/- 0.02 mm, p < 0.05). In the control group, 1 out of 31 patients suffered from symptomatic cerebral infarction and 1 had angina pectoris during the observation period. On the other hand, no subject in the cilostazol group developed cardiovascular events during the study period. At baseline, the diabetic patients given cilostazol had a significantly lower HbA1c level than the control subjects, but the other atherosclerotic risk factors (BMI, blood pressure, and serum lipids) and the duration of diabetes did not differ between the two groups. These results indicate that cilostazol therapy can attenuate the increase of carotid artery IMT in Japanese subjects with type 2 diabetes.
authors.affiliation: Department of Medicine, Metabolism and Endocrinology, Juntendo University, Tokyo 113-8421, Japan.
authors.forename: Naomi
authors.initials: N
authors.lastname: Mitsuhashi
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Sayaka
authors.initials: S
authors.lastname: Kubo
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ogawa
authors.forename: Chisa
authors.initials: C
authors.lastname: Hayashi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Uchino
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Shimizu
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Watada
authors.forename: Masahiko
authors.initials: M
authors.lastname: Kawasumi
authors.forename: Tomio
authors.initials: T
authors.lastname: Onuma
authors.forename: Ryuzo
authors.initials: R
authors.lastname: Kawamori
mesh_terms: D000368:Aged; D001161:Arteriosclerosis / Q000097:blood / Q000150:complications / Q000517:prevention & control*; D001794:Blood Pressure / Q000187:drug effects; D002339:Carotid Arteries / Q000000981:diagnostic imaging / Q000187:drug effects*; D002784:Cholesterol / Q000097:blood; D000077407:Cilostazol; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D012044:Regression Analysis; D013777:Tetrazoles / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood; D017539:Tunica Intima / Q000000981:diagnostic imaging / Q000187:drug effects*; D014463:Ultrasonography; D014527:Uric Acid / Q000097:blood
chemical_list: D002784:Cholesterol; D000077407:Cilostazol; D006442:Glycated Hemoglobin; D010726:Phosphodiesterase Inhibitors; D013777:Tetrazoles; D014280:Triglycerides; D014527:Uric Acid